Shanghai Fosun Pharma's subsidiary to buy GlaxoSmithKline plant
Take me away, mom Animals on the Road	“Water Margin” on eggs Cat the occupier Adorable animals pose like stars Cuddle up together, battling against blizzard Sunshine in the life

 

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. will spend up to 250 million yuan (36 million U.S. dollars) to buy GlaxoSmithKline's Suzhou pharmaceutical factory in east China, according to a Fosun statement released Tuesday.

The deal will allow YaoPharma Co., Ltd., Fosun's Chongqing unit, to acquire all production facilities and authorizations for the GSK plant's chronic hepatitis B drug lamivudine.

The factory achieved a revenue of 656.1 million yuan, with a net profit of 73.98 million yuan in 2018, according to the statement.

Fosun Pharmaceutical's shares closed 0.58 percent higher at 26.24 yuan on Tuesday.

Author： 　　　Source：xinhua　　　 Editor：Yang Fan